Cell MedX Corp (OTCMKTS:CMXC) has closed its registration process with U.S. FDA and has commenced an application process to obtain FDA approval for use of its eBalance equipment as Class 2 non-exempt device. The firm reported that its underway clinical observational study is progressing as anticipated, and as of March 27, the group of trial participants had been surged to 21, with 18 patients having obtained their first eBalance therapies. The firm anticipates that all 30 patients will be initiated into the trial by early April.
Current Observational Clinical Study evaluates the impact of quarter of eBalance treatment as an adjunct therapy, on HbA1c in Type-1 and Type-2 diabetics. The secondary objectives of the study will observe variations from baseline and medical history in insulin sensitivity, diabetic neuropathy, diabetic foot pain and numbness, blood pressure, wound healing and kidney function.
McEnulty, the CEO of Cell MedX, reported that the registration with the U.S. FDA is a thrilling measure step forward, and they are delighted to see that Observational Clinical Study is also advancing as planned, which together will get them that much closer to getting their end objective of assisting people enhance their lives and well-being.
Cell MedX is an early development phase bio-tech firm focused on the development, commercialization and discovery of non-therapeutic and therapeutic products that enhance general wellness and reduce complications linked with medical ailments including, but not confined to, diabetes, high blood pressure, Parkinson’s disease.
In the last trading session, the stock price of Cell MedX declined more than 2% to close the day at $0.320. The decline came at a share volume of 32,158 compared to average share volume of 41,662. After the recent decline, the market cap of firm stands at $12.89 million. The 52-week range of stock stands at 0.12 – 0.46.